NA Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
Description
NA Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
North America natural killer (NK) cell therapeutics market is projected to register a CAGR of 40.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation
North America Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North America natural killer (NK) cell therapeutics market are:
• Increase in patient population with chronic diseases
• Rise in awareness about immunotherapies
• In usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
Market Players
The key market players for North America natural killer (NK) cell therapeutics market are listed below:
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Company Profiles
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
North America natural killer (NK) cell therapeutics market is projected to register a CAGR of 40.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation
North America Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North America natural killer (NK) cell therapeutics market are:
• Increase in patient population with chronic diseases
• Rise in awareness about immunotherapies
• In usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
Market Players
The key market players for North America natural killer (NK) cell therapeutics market are listed below:
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Company Profiles
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Table of Contents
176 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of North America Natural Killer (Nk) Cell Therapeutics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Therapeutics Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Secondary Sources
- 2.11 Assumptions
- 3 Executive Summary
- 3.1 Epidemiology
- 3.2 Pestel Analysis
- 3.3 Porter’s Five Forces Model
- 3.4 Industrial Insights:
- 3.5 Pipeline Analysis
- 4 North America Natural Killer (Nk) Cell Therapeutics Market: Regulations
- 5 Market Overview
- 5.1 Drivers
- 5.1.1 Increase In Usage Of Natural Killer (Nk) Cells For The Treatment Of Cancer And Infectious Diseases
- 5.1.2 Increase In Patient Population With Chronic Diseases
- 5.1.3 Rise In Awareness About Immunotherapies
- 5.1.4 Adoption Of Natural Killer (Nk) Cell Therapy In Emerging Markets
- 5.2 Restraints
- 5.2.1 Lack Of Specificity And Poor In-vivo Survival Of The Cells
- 5.2.2 Adverse Side Effects Of Therapies
- 5.2.3 High Cost Associated With The Therapies
- 5.3 Opportunities
- 5.3.1 Advancement In Natural Killer (Nk) Cell Therapies
- 5.3.2 Strategic Initiatives By Market Players
- 5.3.3 Rise In Expenditure In Healthcare Sector
- 5.4 Challenges
- 5.4.1 Long Approval Time For Immunotherapies
- 5.4.2 Lack Of Specific Treatment By Natural Killer (Nk) Cells
- 5.4.3 Availability Of Alternatives For Tumor Treatment
- 6 North America Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics
- 6.1 Overview
- 6.2 Nk Cell Therapies
- 6.3 Nk Cell Directed Antibodies
- 7 North America Natural Killer (Nk) Cell Therapeutics Market, By Approaches
- 7.1 Overview
- 7.2 Antibody-dependent Cell-mediated Cytotoxicity (Adcc)
- 7.3 Bispecific Antibodies
- 8 North America Natural Killer (Nk) Cell Therapeutics Market, By Application
- 8.1 Overview
- 8.2 Cancer
- 8.2.1 Solid Tumors
- 8.2.2 Hematologic Malignancies
- 8.2.2.1 Multiple Myeloma
- 8.2.2.2 Acute Myeloid Leukemia (Aml)
- 8.2.2.3 Lymphoma
- 8.2.2.4 Others
- 8.2.3 Others
- 8.3 Immunoproliferative Disorders
- 8.4 Acute Infectious Diseases
- 8.5 Gastrointestinal Diseases
- 8.6 Others
- 9 North America Natural Killer (Nk) Cell Therapeutics Market, By End User
- 9.1 Overview
- 9.2 Hospitals
- 9.3 Specialty Clinics
- 9.4 Research & Academic Institutes
- 10 North America Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel
- 10.1 Overview
- 10.2 Hospital Pharmacies
- 10.3 Direct Tender
- 10.4 Others
- 11 North America Natural Killer (Nk) Cell Therapeutics Market, By Region
- 11.1 North America
- 11.1.1 U.S.
- 11.1.2 Canada
- 11.1.3 Mexico
- 12 North America Natural Killer (Nk) Cells Therapeutics Market, Company Landscape
- 12.1 Company Share Analysis: North America
- 13 Swot Analysis
- 14 Company Profile
- 14.1 Merck Kgaa
- 14.1.1 Company Snapshot
- 14.1.2 Recent Financials
- 14.1.3 Product Portfolio
- 14.1.4 Recent Developments
- 14.2 Bristol-myers Squibb Company
- 14.2.1 Company Snapshot
- 14.2.2 Recent Financials
- 14.2.3 Product Portfolio
- 14.2.4 Recent Developments
- 4.3 Glycostem
- 14.3.1 Company Snapshot
- 14.3.2 Product Portfolio
- 14.3.3 Recent Developments
- 14.4 Innate Pharma, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Revenue Analysis
- 14.4.3 Product Portfolio
- 14.4.4 Recent Developments
- 14.5 Regeneron Pharmaceuticals Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Recent Financials
- 14.5.3 Product Portfolio
- 14.5.4 Recent Developments
- 14.6 Takeda Pharmaceutical Company Limited
- 14.6.1 Company Snapshot
- 14.6.2 Recent Financials
- 14.6.3 Product Portfolio
- 14.6.4 Recent Developments
- 14.7 Inmunebio
- 14.7.1 Company Snapshot
- 14.7.2 Revenue Analysis
- 14.7.3 Product Portfolio
- 14.7.4 Recent Developments
- 14.8 Kiadis Pharma
- 14.8.1 Company Snapshot
- 14.8.2 Revenue Analysis
- 14.8.3 Product Portfolio
- 14.8.4 Recent Developments
- 14.9 Acepodia Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Product Portfolio
- 14.9.3 Recent Developments
- 14.10 Affimed Gmbh
- 14.10.1 Company Snapshot
- 14.10.2 Recent Financials
- 14.10.3 Product Portfolio
- 14.10.4 Recent Developments
- 14.11 Biohaven Pharmaceuticals
- 14.11.1 Company Snapshot
- 14.11.2 Revenue Analysis
- 14.11.3 Product Portfolio
- 14.11.4 Recent Developments
- 14.12 Brink Biologics, Inc.
- 14.12.1 Company Snapshot
- 14.12.2 Product Portfolio
- 14.12.3 Recent Development
- 14.13 Cytovia Therapeutics
- 14.13.1 Company Snapshot
- 14.13.2 Product Portfolio
- 14.13.3 Recent Developments
- 14.14 Emercell
- 14.14.1 Company Snapshot
- 14.14.2 Product Portfolio
- 14.14.3 Recent Developments
- 14.15 Fate Therapeutics
- 14.15.1 Company Snapshot
- 14.15.2 Revenue Analysis
- 14.15.3 Product Portfolio
- 14.15.4 Recent Developments
- 14.16 Gamida Cell
- 14.16.1 Company Snapshot
- 14.16.2 Product Portfolio
- 14.16.3 Recent Developments
- 14.17 Icell Gene Therapeutics
- 14.17.1 Company Snapshot
- 14.17.2 Product Portfolio
- 14.17.3 Recent Development
- 14.18 Immunitybio, Inc.
- 14.18.1 Company Snapshot
- 14.18.2 Revenue Analysis
- 14.18.3 Product Portfolio
- 14.18.4 Recent Developments
- 14.19 Multimmune Gmbh
- 14.19.1 Company Snapshot
- 14.19.2 Product Portfolio
- 14.19.3 Recent Developments
- 14.20 Nektar
- 14.20.1 Company Snapshot
- 14.20.2 Revenue Analysis
- 14.20.3 Product Portfolio
- 14.20.4 Recent Developments
- 14.21 Nkarta, Inc.
- 14.21.1 Company Snapshot
- 14.21.2 Product Portfolio
- 14.21.3 Recent Developments
- 14.22 Persongen Biotherapeutics
- 14.22.1 Company Snapshot
- 14.22.2 Product Portfolio
- 14.22.3 Recent Developments
- 14.23 Phio Pharmaceuticals
- 14.23.1 Company Snapshot
- 14.23.2 Product Portfolio
- 14.23.3 Recent Developments
- 15 Questionnaire
- 16 Related Reports
- List Of Tables
- Table 1 North America Natural Killer (Nk) Cell Therapeutics Market, Pipeline Analysis
- Table 2 North America Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 3 North America Nk Cell Therpaies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 4 North America Nk Cell Directed Antibodies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 5 North America Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 6 North America Antibody-dependent Cell-mediated Cytotoxicity (Adcc) In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 7 North America Bi-specific Antibodies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 8 North America Natural Killer (Nk) Cell Therapeutics Market, By Application, 2019-2027 (Usd Million)
- Table 9 North America Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 10 North America Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 11 North America Hematologic Malignancies In Cancer Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 12 North America Others In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 13 North America Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 14 North America Hospitals In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 15 North America Specialty Clinics In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 16 North America Research And Academic Institutes In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 17 North America Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2027 (Usd Million)
- Table 18 North America Hospital Pharmacies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2027 (Usd Million)
- Table 19 North America Direct Tender In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2027 (Usd Million)
- Table 20 North America Others In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 21 North America Natural Killer (Nk) Cell Therapeutics Market, By Country, 2018-2029 (Usd Million)
- Table 22 North America Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 23 North America Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 24 North America Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 25 North America Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 26 North America Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 27 North America Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 28 North America Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 29 U.S. Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 30 U.S. Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 31 U.S. Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 32 U.S. Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 33 U.S. Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 34 U.S. Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 35 U.S. Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 36 Canada Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 37 Canada Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 38 Canada Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 39 Canada Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 40 Canada Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 41 Canada Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 42 Canada Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 43 Mexico Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 44 Mexico Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 45 Mexico Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 46 Mexico Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 47 Mexico Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 48 Mexico Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 49 Mexico Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- List Of Figures
- Figure 1 North America Natural Killer (Nk) Cell Therapeutics Market: Segmentation
- Figure 2 North America Natural Killer (Nk) Cell Therapeutics Market : Data Triangulation
- Figure 3 North America Natural Killer (Nk) Cell Therapeutics Market: Droc Analysis
- Figure 4 North America Natural Killer (Nk) Cell Therapeutics Market: North America Vs Regional Market Analysis
- Figure 5 North America Natural Killer (Nk) Cell Therapeutics Market: Company Research Analysis
- Figure 6 North America Natural Killer (Nk) Cell Therapeutics Market: Multivariate Modelling
- Figure 7 North America Natural Killer (Nk) Cell Therapeutics Market: Interview Demographics
- Figure 8 North America Natural Killer (Nk) Cell Therapeutics Market: Dbmr Market Position Grid
- Figure 9 North America Natural Killer (Nk) Cell Therapeutics Market: Vendor Share Analysis
- Figure 10 North America Natural Killer (Nk) Cell Therapeutics Market: Segmentation
- Figure 11 North America Is Expected To Dominate And Asia-pacific Is Growing With The Fastest Pace In The North America Natural Killer (Nk) Cell Therapeutics Market In The Forecast Period Of 2022 To 2029
- Figure 12 Increase In Usage Of Natural Killer Cells For The Treatment Of Cancer And Infectious Diseases And Rise In The Awareness About Immunotherapies Is Driving The North America Natural Killer (Nk) Cell Therapeutics Market In The Forecast Period Of 2022 To 2029
- Figure 13 Nk Cell Therapies Segment Is Expected To Account For The Largest Share Of The North America Natural Killer (Nk) Cell Therapeutics Market In 2022 & 2029
- Figure 14 Drivers, Restraints, Opportunities, And Challenges Of North America Natural Killer (Nk) Cell Therapeutics Market
- Figure 15 North America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, 2021
- Figure 16 North America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, 2022-2029 (Usd Million)
- Figure 17 North America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, Cagr (2022-2029)
- Figure 18 North America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, Lifeline Curve
- Figure 19 North America Natural Killer (Nk) Cell Therapeutics Market: By Approaches, 2021
- Figure 20 North America Natural Killer (Nk) Cell Therapeutics Market: By Approaches, 2022-2029 (Usd Million)
- Figure 21 North America Natural Killer (Nk) Cell Therapeutics Market: By Approaches, Cagr (2022-2029)
- Figure 22 North America Natural Killer (Nk) Cell Therapeutics Market: By Approaches, Lifeline Curve
- Figure 23 North America Natural Killer (Nk) Cell Therapeutics Market: By Application, 2020
- Figure 24 North America Natural Killer (Nk) Cell Therapeutics Market: By Application, 2022-2029 (Usd Million)
- Figure 25 North America Natural Killer (Nk) Cell Therapeutics Market: By Application, Cagr (2022-2029)
- Figure 26 North America Natural Killer (Nk) Cell Therapeutics Market: By Application, Lifeline Curve
- Figure 27 North America Natural Killer (Nk) Cell Therapeutics Market: By End User, 2021
- Figure 28 North America Natural Killer (Nk) Cell Therapeutics Market: By End User, 2022-2029 (Usd Million)
- Figure 29 North America Natural Killer (Nk) Cell Therapeutics Market: By End User, Cagr (2022-2029)
- Figure 30 North America Natural Killer (Nk) Cell Therapeutics Market: By End User, Lifeline Curve
- Figure 31 North America Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, 2021
- Figure 32 North America Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, 2022-2029 (Usd Million)
- Figure 33 North America Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, Cagr (2022-2029)
- Figure 34 North America Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, Lifeline Curve
- Figure 35 North America Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 36 North America Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 37 North America Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 38 North America Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 39 North America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 40 North America Natural Killer (Nk) Cell Therapeutics Market: Company Share 2021 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
